Hizlaria / Ponente: María José Barrero, PhD – Lider del grupo The CNIO-Lilly Epigenetics Laboratory. CNIO, Madrid.
Data / Fecha: 2019ko irailak 5 / 5 de septiembre de 2019.
Ordua / Hora:  12:00 – 14:00.
Lekua / Lugar: Biodonostia OIIkoEkitaldi Aretoan, 0.Solairua. / IIS Biodonostia, Salón de Actos, Planta 0.

Laburpena / Resumen:

Some epigenetic drugs are currently used to treat certain types of cancer and many others are in clinical or preclinical trials. However, despite their therapeutic potential, lack of full understanding of the molecular mechanisms of action of these drugs has hampered clinical advances. Understanding such mechanisms is essential for proper patient tailoring and to identify effective combinations with other cancer therapies.

In the last decade bromodomains have emerged as potential targets for cancer treatment. Bromodomains bind acetylated lysines in histone tails and are present in 46 different human proteins. Our work has elucidated the mechanism of action CREBBP/EP300 bromodomain inhibitors in transcriptionally addicted cancer cells. In other cancer models, we have used inhibitors of epigenetic repressors to activate innate immunity pathways, as well as the expression of tumor-specific antigens, which suggest their potential use in combination with immunotherapeutic strategies.